Show simple item record

dc.contributor.authorQuispe-Moore, L.
dc.contributor.authorVences, M.A.
dc.contributor.authorSaquisela-Alburqueque, V.
dc.contributor.authorQuispe-Huamani, E.
dc.contributor.authorCortez-Salazar, L.
dc.contributor.authorSeminario, W.G.
dc.contributor.authorSuarez-Loro, M.
dc.contributor.authorPortocarrero-Nieto, E.
dc.contributor.authorAlva-Diaz, C.
dc.contributor.authorAlarcon-Ruiz, C.A.
dc.date.accessioned2025-10-31T18:39:34Z
dc.date.available2025-10-31T18:39:34Z
dc.date.issued2023
dc.identifier.urihttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/1979
dc.identifier.urihttps://hdl.handle.net/20.500.12805/5738
dc.description.abstractBackground: Most of hospitalized patients with COVID-19 have had neurological manifestations. However, biomarkers for specific neurological manifestations and how these affect clinical outcomes are still unclear. Objective: To describe the frequency of neurological manifestations in patients hospitalized with COVID-19 and analyze their relationship with biomarkers and relevant clinical outcomes. Methods: This retrospective cohort study included adult patients hospitalized due to COVID-19 with at least one neurological manifestation. Headache, anosmia, ageusia, and polyneuromyopathy were classified as nonspecific neurological manifestations, whereas epileptic seizures, decreased level of consciousness, delirium, encephalitis, abnormal movements, ataxia, and cerebrovascular events as specific. Assessed associations: a) clinical and laboratory covariates with the presentation of a specific neurological manifestation; b) the relationship between specific neurological manifestation and COVID-19 severity, mechanical ventilation, and mortality; and c) duration of mechanical ventilation and polyneuromyopathy. Results: Of the 338 patients included in the study, 61, 2% had severe COVID-19, 25, 2% required mechanical ventilation, and 23, 7% died. The most frequent neurological manifestations were headache (68, 3%), delirium (41, 9%), decreased level of consciousness (40, 8%), and polyneuromyopathy (21, 8%). High serum D-dimer levels and lymphopenia were associated with a specific neurological manifestation. At least one specific neurological manifestation was found in 39, 9% of patients, and these group was associated with mechanical ventilation and mortality. Finally, a longer duration on mechanical ventilation was associated with a higher frequency of polyneuromyopathy. Conclusion: Specific neurological manifestations were frequent in hospitalized patients with COVID-19 and are associated with greater clinical and laboratory severity.en_US
dc.formatapplication/pdf
dc.language.isoeng
dc.publisherMedical Body of the Almanzor Aguinaga Asenjo National Hospital
dc.relation.ispartofurn:issn:2227-4731
dc.rightshttps://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectSDG 3en_US
dc.subjectMental Health Impacts of COVID-19 Pandemicen_US
dc.subjectNeurological Impacts of COVID-19 Infectionen_US
dc.titleNeurological manifestations and clinical outcomes in hospitalized patients with COVID-19: Retrospective cohort in a Peruvian hospitalen_US
dc.typehttps://purl.org/coar/resource_type/c_2df8fbb1
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.02.25
dc.type.otherResearch article
dc.identifier.journalRevista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo
dc.type.versionhttps://purl.org/coar/version/c_970fb48d4fbd8a85


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://purl.org/coar/access_right/c_abf2
Except where otherwise noted, this item's license is described as https://purl.org/coar/access_right/c_abf2